KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Short-term Investments: 2009-2024

Historic Short-term Investments for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $436.4 million.

  • Acadia Pharmaceuticals' Short-term Investments rose 43.60% to $589.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $589.0 million, marking a year-over-year increase of 43.60%. This contributed to the annual value of $436.4 million for FY2024, which is 74.42% up from last year.
  • As of FY2024, Acadia Pharmaceuticals' Short-term Investments stood at $436.4 million, which was up 74.42% from $250.2 million recorded in FY2023.
  • Acadia Pharmaceuticals' Short-term Investments' 5-year high stood at $436.4 million during FY2024, with a 5-year trough of $250.2 million in FY2023.
  • Its 3-year average for Short-term Investments is $329.5 million, with a median of $302.0 million in 2022.
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 39.75% in 2020, then surged by 74.42% in 2024.
  • Acadia Pharmaceuticals' Short-term Investments (Yearly) stood at $305.9 million in 2020, then grew by 22.01% to $373.3 million in 2021, then decreased by 19.10% to $302.0 million in 2022, then dropped by 17.14% to $250.2 million in 2023, then surged by 74.42% to $436.4 million in 2024.